Antitumor Activity of the Antimicrobial Peptide Magainin II against Bladder Cancer Cell Lines

European Urology

Volumn 50, Issue 1, 2006, Pages 141-147

  Lehmann, Jan ^a   Retz, Margitta ^b   Sidhu, Sukhvinder S ^b   Suttmann, Henrik ^a   Sell, Michael ^a   Paulsen, Friedrich ^c   Harder, Jürgen ^d   Unteregger, Gerhard ^a   Stöckle, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Antimicrobial peptides; Bladder cancer; Cell proliferation; Cytotoxicity; Magainin

Indexed keywords

ANTINEOPLASTIC AGENT; BROXURIDINE; LACTATE DEHYDROGENASE; MAGAININ 2; POLYPEPTIDE ANTIBIOTIC AGENT;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CHANNEL GATING; COLORIMETRY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; ENZYME ASSAY; ENZYME RELEASE; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICROSCOPY, ELECTRON, SCANNING; URINARY BLADDER NEOPLASMS; XENOPUS PROTEINS;

EID: 33744933929     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.12.043     Document Type: Article

References (21)

1. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
2. Witjes J.A. Bladder carcinoma in situ in 2003: state of the art. Eur Urol 45 (2004) 142-146
3. Cheng C.W., Chan S.F., Chan L.W., Chan C.K., Ng C.F., Cheung H.Y., et al. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guérin and epirubicin as adjuvant therapy in superficial bladder cancer. Int J Urol 12 (2005) 449-455
4. Böhle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
5. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
6. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 84 (1987) 5449-5453
7. Maloy W.L., and Kari U.P. Structure-activity studies on magainins and other host defense peptides. Biopolymers 37 (1995) 105-122
8. Zasloff M., Martin B., and Chen H.C. Antimicrobial activity of synthetic magainin peptides and several analogues. Proc Natl Acad Sci USA 85 (1988) 910-913
9. Matsuzaki K., Sugishita K., Harada M., Fujii N., and Miyajima K. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. Biochim Biophys Acta 1327 (1997) 119-130
10. Cruciani R.A., Barker J.L., Zasloff M., Chen H.C., and Colamonici O. Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. Proc Natl Acad Sci 88 (1991) 3792-3796
11. Ohsaki Y., Gazdar A.F., Chen H.C., and Johnson B.E. Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res 52 (1992) 3534-3538
12. Baker M.A., Maloy W.L., Zasloff M., and Jacob L.S. Anticancer efficacy of magainin2 and analogue peptides. Cancer Res 53 (1993) 3052-3057
13. Soballe P.W., Maloy W.L., Myrga M.L., Jacob L.S., and Herlyn M. Experimental local therapy of human melanoma with lytic magainin peptides. Int J Cancer 60 (1995) 280-284
14. Park Y., Lee D.G., and Hahm K.S. Antibiotic activity of Leu-Lys rich model peptides. Biotechnol Lett 25 (2003) 1305-1310
15. Bessalle R., Kapitkovsky A., Gorea A., Shalit I., and Fridkin M. All-D-magainin: chirality, antimicrobial activity and proteolytic resistance. FEBS Lett 274 (1990) 151-155
16. Zwergel T., Kakirman H., Schorr H., Wullich B., and Unteregger G. A new serial transfer explant cell culture system for human prostatic cancer tissues preventing selection toward diploid cells. Cancer Genet Cytogenet 101 (1998) 16-23
17. Matsuzaki K., Harada M., Funakoshi S., Fujii N., and Miyajima K. Physicochemical determinants for the interactions of magainins 1 and 2 with acidic lipid bilayers. Biochim Biophys Acta 1063 (1991) 162-170
18. Peck-Miller K.A., Darveau R.P., and Fell H.P. Identification of serum components that inhibit the tumoricidal activity of amphiphilic alpha helical peptides. Cancer Chemother Pharmacol 32 (1993) 109-115
19. Lincke C.R., van der Bliek A.M., Schuurhuis G.J., van d V., Smit J.J., and Borst P. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res 50 (1990) 1779-1785
20. Endicott J.A., and Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58 (1989) 137-171
21. Witjes J.A., van der Heijden A.G., Vriesema J.L., Peters G.J., Laan A., and Schalken J.A. Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 45 (2004) 182-186